Synapse - Find an Expert

5913 Results

Immune escape after allogeneic hematopoietic cell transplantation in pediatric patients with acute myeloid leukemia

Meeting Abstract

Shahid, S.; Ceglia, N.; Le Luduec, J. B.; McPherson, A.; Spitzer, B.; Bojilova, V.; Panjwani, M. K.; Roshal, M.; Shah, S.; Abdel-Wahab, O.; more...
Blood (2022)

Fulltext@MSK | Save

Characterization of a large cohort of patients with nodal marginal zone lymphoma shows prolonged survival, time-to-treatment, and time-to-transformation

Meeting Abstract

Stuver, R.; Drill, E.; Qualls, D.; Okwali, M.; Batlevi, C. L.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; more...
Blood (2022)

Fulltext@MSK | Save

Molecular profiling across lymphoma subtypes using MSK-impact next generation sequencing

Meeting Abstract

Batlevi, C. L.; Drill, E.; Okwali, M.; Ptashkin, R.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
Blood (2022)

Fulltext@MSK | Save

Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma

Meeting Abstract

Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
Blood (2022)

Fulltext@MSK | Save

Erythroid and megakaryocytic differentiation program in JAK2-mutated acute myeloid leukemia with or without antecedent myeloproliferative neoplasm

Meeting Abstract

Liu, Y.; Sethi, S.; Koche, R.; Gao, Q.; Dilip, D.; Glass, J. L.; Galera, P. K.; Persaud, S.; Mishra, T.; Sun, X.; more...
Blood (2022)

Fulltext@MSK | Save

Whole genome sequencing comparison of acute myeloid leukemia at presentation and remission predicts patient outcome

Meeting Abstract

Moffitt, A. B.; Alexander, J.; Stepansky, A.; Famulare, C.; Lopez, C. A.; Hakim, N.; Wu, V.; Wang, Z.; Kolitz, J. E.; Chiorazzi, N.; more...
Blood (2022)

Fulltext@MSK | Save

Quantitative cytogenetic analysis with karyoParser allows for more precise identification of disease biology, clonal evolution, and etiology of relapse in acute myeloid leukemia

Meeting Abstract

Dilip, D.; Derkach, A.; Menghrajani, K.; Goldberg, A. D.; May, H.; Klimek, V. M.; Galera, P. K.; Xiao, W.; Zhang, Y.; Elemento, O.; more...
Blood (2022)

Fulltext@MSK | Save

A Phase 1b dose escalation and expansion study of SNDX-5613, azacitidine (AZA) and venetoclax (VEN) in newly diagnosed, patients ≥ 60 years with untreated NPM1-mutated/ FLT3-wild type AML or KMT2A-rearranged acute myeloid leukemia (AML)

Meeting Abstract

Zeidner, J. F.; Foster, M. C.; Johnson, M.; Huang, Y.; Swords, R. T.; Stein, E.; Foran, J. M.; Baer, M. R.; Stock, W.; Madanat, Y. F.; more...
Blood (2022)

Fulltext@MSK | Save

The second generation type II JAK2 inhibitor, AJ1-10502, demonstrates enhanced selectivity, improved therapeutic efficacy and reduced mutant cell fraction compared to type I JAK2 inhibitors in models of myeloproliferative neoplasms (MPNs)